Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Enlivex Therapeutics Ltd ENLV

Healthcare Biotechnology
Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages... see more

Recent & Breaking News (NDAQ:ENLV)

Bioblast Pharma Reports First Quarter 2017 Financial Results

GlobeNewswire May 26, 2017

Bioblast Pharma Announces Plans in Response to Nasdaq Notifications Regarding Stockholders’ Equity and Minimum Bid Requirements

GlobeNewswire April 17, 2017

Bioblast Announces Termination of Securities Offering

GlobeNewswire April 6, 2017

Bioblast Pharma Announces Termination of Securities Offering

GlobeNewswire April 6, 2017

Bioblast Pharma Announces Receipt of Nasdaq Notification Regarding Stockholders’ Equity

GlobeNewswire March 10, 2017

Bioblast Pharma Reports Fourth Quarter and Year End 2016 Financial Results

GlobeNewswire February 24, 2017

Bioblast Pharma Provides Clinical and Development Updates on Trehalose as a Potential Therapeutic for OPMD and Other Neurodegenerative Diseases

GlobeNewswire February 1, 2017

Bioblast Pharma to Host Key Opinion Leader Lunch Focused on Orphan Neurological Diseases on February 2

GlobeNewswire January 26, 2017

Bioblast Announces Phase 2a Results of Trehalose in Patients with Spinocerebellar Ataxia Type 3 (SCA3)

GlobeNewswire January 18, 2017

15 Biggest Mid-Day Losers For Tuesday

Benzinga.com  November 29, 2016

Bioblast Pharma Reports Third Quarter 2016 Financial Results

GlobeNewswire November 29, 2016

Bioblast Announces Results of Trehalose Clinical Study

GlobeNewswire October 24, 2016

Bioblast’s Special Medical Advisor to Make a Presentation Today On Trehalose as a Potential Therapeutic Agent for OPMD

GlobeNewswire September 26, 2016

Bioblast Pharma Reports Results of a Clinical Trial of Trehalose in Oculopharyngeal Muscular Dystrophy (OPMD) Patients

GlobeNewswire September 12, 2016

Bioblast Pharma Announces Presentation at the 18th Annual Rodman & Renshaw Global Investment Conference on September 12, 2016

GlobeNewswire September 7, 2016

Bioblast Pharma Reports Second Quarter 2016 Financial Results

GlobeNewswire August 25, 2016

Bioblast Pharma Updates Corporate Plans

GlobeNewswire June 9, 2016

Bioblast Pharma Reports First Quarter 2016 Financial Results

GlobeNewswire May 25, 2016

Four Trending Stocks That Require Your Attention on April 15th

Accesswire April 15, 2016

BioBlast Pharma to Present Final HOPEMD Phase 2 Clinical Study Results of Trehalose in Oculopharyngeal Muscular Dystrophy at the American Academy of Neurology (AAN) 2016 Annual Meeting

GlobeNewswire April 14, 2016